SCHEMBL1748569

SCHEMBL1748569

COc1ccccc1Cc1c(Cl)ncnc1NC1CCN(Cc2cc(OC(C)C)cc(OC(C)C)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 6/20 0.51
SSTR5 P35346 1/20 0.49
MEN1 O00255 4/20 0.45
KMT2A Q03164 3/20 0.45
POLB P06746 1/20 0.45
SIGMAR1 Q99720 1/20 0.42
EZH2 Q15910 1/20 0.42
EHMT2 Q96KQ7 3/20 0.41
KDM1A O60341 1/20 0.41
RCOR1 Q9UKL0 1/20 0.41
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
BACE1 P56817 1/20 0.41
RAB9A P51151 2/20 0.40
RXFP1 Q9HBX9 2/20 0.40
LMNA P02545 1/20 0.40
NOD2 Q9HC29 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1748386 0.87 SSTR5 (0.48) NSD2SSTR5MEN1KMT2ASIGMAR1
SCHEMBL1748519 0.86 NSD2 (0.52) NSD2SSTR5MEN1KMT2AEZH2
SCHEMBL1748205 0.81 SSTR5 (0.50) NSD2SSTR5MEN1KMT2ASIGMAR1
SCHEMBL1748536 0.80 SSTR5 (0.53) NSD2SSTR5MEN1KMT2AACHE
SCHEMBL1748210 0.80 SSTR5 (0.49) NSD2SSTR5MEN1KMT2AACHE
SCHEMBL1748423 0.80 MEN1 (0.48) NSD2SSTR5MEN1KMT2ASIGMAR1
SCHEMBL1748221 0.80 SSTR5 (0.51) NSD2SSTR5MEN1KMT2AACHE
SCHEMBL1748322 0.76 SSTR5 (0.52) NSD2SSTR5EZH2EHMT2KDM1A
SCHEMBL1748544 0.75 NSD2 (0.55) NSD2SSTR5MEN1KMT2AMCHR1
SCHEMBL1748444 0.73 GRIN2B (0.53) SSTR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968568-B2 [1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(2-chloro-pyrimidin-4-yl)-amine; somatostatin receptor subtype 5 (SSTR5) antagonists; diabetes mellitus HOFFMANN-LA ROCHE INC. (US) 2011-06-28 US disclosed
EP-2044054-B1 PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY HOFFMANN LA ROCHE (CH) 2011-06-08 EP disclosed
US-20100069413-A1 Pyrimidine and Quinazoline Derivatives CHRIST ANDREAS D 2010-03-18 US disclosed
US-7674804-B2 Pyrimidine and quinazoline derivatives as SST5 modulators HOFFMANN-LA ROCHE INC. (US) 2010-03-09 US disclosed
EP-2044054-A2 PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY F. Hoffmann-Roche AG (CH) 2009-04-08 EP disclosed
US-20080045550-A1 Pyrimidine and quinazoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 2008-02-21 US disclosed
WO-2008000692-A2 PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069413-A1 Pyrimidine and Quinazoline Derivatives SSTR5, SSTR3, NPY5R NSD2 3810/4885SSTR5 1/4885MEN1 1238/4885
US-20080045550-A1 Pyrimidine and quinazoline derivatives SSTR5, SSTR3, NPY5R NSD2 3810/4885SSTR5 1/4885MEN1 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.